Whats interesting about this is that Biotron is the Smaallest and the Least valued in this Sector of HCV Development STAGES...
Protease inhibitors Company Phase
Boceprevir Merck Approved
Telaprevir Vertex / Tibotec Approved
BI 201335 Boehringer Ingelheim Pharma Phase III
TMC435 Tibotec Phase III
Vaniprevir (MK-7009) Merck Phase II
RG7227 (Danoprevir) InterMune / Genentech Phase II
ABT-450 Abbott / Enanta Phase II
ACH-1625 Achillion Phase II
BIT225 Biotron Phase II
BMS 650032 Bristol-Myers Squibb Phase II
GS-9256 Gilead Phase II
MK-5172 Merck Phase II
biolinerx shares pop on hep c pact, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 512798 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1050263 | 5 |
View Market Depth
| Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |